Kirin Holdings Company,Limited FY2026 Q2 Earnings Report

Quick View

Executive Summary

Kirin Holdings’ 2026 fiscal year Q2 results featured higher revenue and substantially higher profit, with structural improvements in profitability driving performance. Revenue was ¥12,178.8B (+7.2% year on year), Operating Income was ¥1,290.4B (+87.8%), Profit Before Tax (Ordinary Income is not used because the company applies IFRS) was ¥1,508.5B (+80.1%), and Net Income was ¥1,161.0B (+92.0%; attributable to owners of the parent was ¥1,017.2B, +92.5%). The primary driver of the increase in profit was the improvement in the gross margin and decline in the SG&A ratio, which lifted the Operating Income margin to 10.6%, supplemented by the higher margins of the pharmaceutical business.

Factors Affecting Performance

【Revenue】Revenue was ¥12,178.8B, representing a 7.2% year-on-year increase. By segment, Alcoholic Beverages was the largest segment (42.5% of total, revenue of ¥5,178.4B, +5.1%), followed by Non-Alcoholic Beverages (24.2%, ¥2,948.8B, +8.5%) and Pharmaceuticals (21.6%, ¥2,634.9B, +14.3%). Strong growth in Pharmaceuticals and improvements in pricing and product mix drove the increase in revenue.

【Profit and Loss】Operating Income rose substantially to ¥1,290.4B (+87.8%). The gross margin improved to 48.7% from the previous year, while the SG&A ratio declined to 38.1%, resulting in operating leverage. Share of profit of investments accounted for using the equity method of ¥203.1B boosted Profit Before Tax, which reached ¥1,508.5B (+80.1%), while Net Income was ¥1,161.0B (+92.0%). Operating Income in the Pharmaceuticals segment was ¥605.4B (+80.7%, margin of 23.0%), making it the core driver of company-wide profit growth. Together with Alcoholic Beverages at ¥620.9B (+16.8%, margin of 12.0%), the two segments have established themselves as the company’s main earnings pillars. In conclusion, the results featured both revenue and profit growth, with the rate of profit growth substantially exceeding the rate of revenue growth, indicating high-quality earnings.

Segment Analysis

Segment profit margins were 23.0% for Pharmaceuticals, 12.0% for Alcoholic Beverages, 10.5% for Non-Alcoholic Beverages, and 8.1% for Health Science, in that order. Pharmaceuticals recorded a 14.3% increase in revenue versus an 80.7% increase in Operating Income, with profit growth substantially outpacing revenue growth and demonstrating a marked qualitative improvement in the earnings structure. Alcoholic Beverages recorded a 5.1% increase in revenue versus a 16.8% increase in profit, indicating the effects of improvements in pricing and product mix. Meanwhile, Other segments recorded revenue of ¥128.2B (-9.3%) and an Operating Loss of ¥14.8B. Although their impact on company-wide profit is limited, they remain low-profitability areas. Overall, a notable feature is that the portfolio’s center of gravity is shifting toward high-margin businesses, particularly Pharmaceuticals and Alcoholic Beverages.

Key Financial Indicators

【Profitability】The Operating Income margin improved substantially to 10.6% from 6.0% in the previous year, while the Net Income margin rose to 9.5% (8.3% based on net income attributable to owners of the parent). Both the gross margin of 48.7% and the SG&A ratio of 38.1% improved from the previous year, with pricing and product mix improvements and cost efficiencies supporting the increase in margins.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥1,373.5B, equivalent to 1.18 times consolidated Net Income, indicating sound cash flow support for earnings.【Investment Efficiency】ROE was 6.9%, with the contribution of Share of profit of investments accounted for using the equity method (¥203.1B) to Profit Before Tax also evident to a certain extent.【Financial Soundness】The Equity Ratio was 40.0%, improving from 36.8% in the previous year, while interest-bearing debt was trending downward due to bond redemptions and debt repayments. Total assets decreased slightly to ¥34,012.8B (¥34,940.4B in the previous year), while net assets increased to ¥16,806.7B (¥15,951.5B in the previous year), strengthening the capital structure.

Cash Flow Analysis

Operating Cash Flow (OCF) increased substantially by 104.2% year on year to ¥1,373.5B, primarily due to a decrease in trade receivables (+¥1,149.7B), while inventories (-¥91.1B) and a decrease in trade payables (-¥310.2B) were headwinds. Investing Cash Flow was positive at ¥536.6B, as other items, including the recovery of investments and loans, exceeded capital expenditures of ¥652.5B. Financing Cash Flow was -¥1,624.7B, reflecting dividend payments of ¥299.8B, share repurchases of ¥345.5B, and bond redemptions and debt repayments. Free Cash Flow (OCF + Investing Cash Flow) was ample at ¥1,910.1B, comfortably covering shareholder returns comprising dividends and share repurchases. Cash and cash equivalents at the end of the period were ¥1,680.8B.

Earnings Quality

The improvement in profit during the current period was primarily driven by stronger earning power in the core business. Against Operating Income of ¥1,290.4B, finance income of ¥125.5B and finance costs of ¥110.4B were almost offset, while Share of profit of investments accounted for using the equity method of ¥203.1B boosted Profit Before Tax. However, this remained a modest amount relative to revenue and did not represent excessive dependence. Deducting income taxes and other taxes of ¥347.5B (an effective tax rate of approximately 23.0%) from Profit Before Tax of ¥1,508.5B resulted in Net Income of ¥1,161.0B, which is within an explainable range from a tax-rate perspective, with no unusual adjustments observed. The fact that OCF has remained above Net Income indicates that earnings are supported by cash flow, and earnings quality can be assessed as sound.

Earnings Forecast and Guidance

Against the Full-Year forecast (Revenue of ¥24,800.0B, Net Income of ¥1,940.0B, and EPS of ¥200.00), the first-half progress rates were 49.1% for Revenue and 59.8% for consolidated Net Income. The fact that progress in Net Income is outpacing progress in Revenue indicates that first-half profit growth is ahead of the Full-Year plan. The revision to the earnings forecast during the current quarter also suggests that first-half results have changed from the assumptions used when the plan was formulated. Trends in raw-material costs and advertising investment during the second half will influence the sustainability of the pace of progress.

Shareholder Returns

The interim dividend was ¥38 per share, while the Full-Year forecast is ¥76 (the previous year was ¥37, with the Full-Year figure previously undetermined; the company is planning an increase in dividends this fiscal year). The Payout Ratio against the company’s planned EPS of ¥200 is 38.0%. Share repurchases of ¥345.5B were conducted, bringing total shareholder returns, including dividends of ¥299.8B, to approximately ¥645B. Coverage of total returns by Free Cash Flow of ¥1,910.1B is high, and the current return policy is not excessive relative to cash-generation capacity.

Risk Factors

1. Deterioration in working capital efficiency: Inventories of -¥91.1B and trade payables of -¥310.2B indicate movements that put pressure on funds, offset by a substantial decrease in trade receivables, which contributed +¥1,149.7B in cash. The impact of working capital fluctuations on OCF requires continued monitoring.

2. Increased earnings dependence on the Pharmaceuticals segment: Operating Income from Pharmaceuticals was ¥605.4B (margin of 23.0%), making it the core contributor to company-wide profit. The impact of the segment’s growth rate and profit margin on company-wide performance has therefore become relatively greater.

3. Level of goodwill and intangible assets: Goodwill of ¥5,495.7B and intangible fixed assets of ¥6,897.7B together account for approximately 36.5% of total assets. They represent 32.7% of net assets, requiring attention to the risk of valuation revisions if the business environment changes.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (food_beverage)

Profitability and Returns

The Company’s Operating Income margin and Net Income margin have been calculated as levels verifiable within the industry.

Growth and Capital Efficiency

The Revenue growth rate was 7.2%, and its relative position within the food and beverage industry will become clearer as median data is expanded.

※Source: Compiled by the Company

Key Takeaways from the Results

1. The Operating Income margin improved substantially from 6.0% in the previous year to 10.6%, indicating structural profitability improvements driven by pricing and product mix and cost efficiencies. Simultaneous improvement in the gross margin and SG&A ratio suggests a qualitative change in business operations rather than a one-off factor.

2. The Pharmaceuticals segment’s profit margin of 23.0% was substantially above the company-wide average, and segment growth (revenue +14.3%, profit +80.7%) led company-wide profit growth. The shift in the business portfolio’s center of gravity toward highly profitable areas is a distinctive feature of the earnings structure.

3. OCF remained above Net Income, and Free Cash Flow of ¥1,910.1B comfortably covered dividends, share repurchases, and capital expenditures. Meanwhile, movements in inventories and trade payables also indicate pressure from a working capital perspective, making trends in the components of cash flow an area for future observation.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,862–¥1,972 for cost of equity ±1%, and ¥1,911–¥1,923 for ω ±0.1.

Notes:

• Because progress in Net Income against the Full-Year forecast (64%) exceeds the standard level (50%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies ahead of plan tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Goodwill represents a high proportion of net assets, and the assumptions would change significantly if impairment occurred.
• Net assets as of the end of the quarter are used (there is a timing gap relative to the Full-Year forecast).

(Calculation model: Residual income model / Interest-rate reference month: 2026-07 / This value does not predict or guarantee future share prices)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---